

Name	Name of Ineligible Company(s) (n/a if none)	Nature of Relationship(s) (n/a if none)
Ahn, David	(1) Lilly Diabetes, Novo Nordisk, Xeris Pharmaceuticals, Abbott, Insulet, Mannkind, Dexcom, Sequel (2) Lilly Diabetes, Ascensia Diabetes Care, Mannkind (3) Novo, Lilly, Sequel, Medtronic, Tandem, Fractal, Endogenex, Abbvie, Senseonics	(1) Speakers Bureau (2) Consultant (3) Research Funding
Al-Ward, Ruaa	(1) Xeris Pharmaceuticals, Camurus (2) Corcept	(1) Advisory Board (2) Consultant
Aleppo, Grazia	(1) Dexcom, Insulet, Eli-Lilly, Medscape, Tandem Diabetes Care, Jaeb Center for Healthcare Research, Tandem Diabetes Care and Medscape (2) Abbvie, Bayer Health, Fractyl Health, Insulet, MannKind, Tandem Diabetes Care, Welldoc (3) Tandem, Medscape	(1) Stock/Consultant (2) Research Funding (3) Consultant
Almandoz, Jaime	(1) AbbVie, Amgen, Haleon, Kailera, Metsera/Pfizer, Nestlé, Rivus, Rhythm, Boehringer Ingelheim, Eli Lilly, Novo Nordisk	(1) Consultant
Aloi, Joseph	(1) Medtronic, Biomea Covalent (2) Abbott (3) Recordati	(1) Research Funding (2) Stock Ownership (3) Consultant
Anastasopoulou, Catherine	(1) HSX, IQVIA, JDRF (2) Ascendis (3) Sanofi, Radius	(1) Research Funding (2) Speakers Bureau (3) Consultant
Athimulam, Shobana	(1) Corcept, Recordati	(1) Consultant
Bellini, Natalie	(1) Abbott, Dexcom, Medtronic, Embecta, Sanofi (2) Medtronic, Sanofi	(1) Speaker (2) Advisory Boards
Bhan, Arti	(1) Abbott, Lily, Novo Nordisk	(1) Research Funding

Bianco, Antonio	(1) AbbVie, Acella, Synthonics, Xeris (2) AbbVie, Xeris	(1) Stock Ownership (2) Consultant
Clements, Jennifer	(1) Novo Nordisk, Eli Lilly (2) Embecta, Xeris	(1) Speakers Bureau (2) Consultant
Correa, Ricardo	(1) Recordati (2) Sanofi, Neurocrine Biosciences(3) Moderna	(1) Research Funding (2) Speakers Bureau (3) Consultant
Cusano, Natalie	(1) Alexion Pharmaceuticals, Ascendis Pharma, Extend Biosciences; (2) Shire/Takeda Pharmaceutical Company, Ascendis Pharma (3) Alexion Pharmaceuticals	(1) Consultant (2) Research Funding (3) Speakers Bureau
Cusi, Kenneth	(1) Boehringer Ingelheim, Echosens, Inventiva, LabCorp and Perspectum (2) Arrowhead, 89Bio, Boehringer Ingelheim, BMS, Dexcom, Echosens, Eli Lilly & Co, GSK, MGGM, Novo Nordisk, Sagimet Biosciences, Terns Pharmaceuticals and Zealand Pharma.	(1) Research Funding (2) Consultant
Desai, Kaniksha	(1) Veracyte, Veridian	(1) Consultant
Desai, Navtika	(1) Amgen; (2) Novo Nordisk, Astellas, Amgen	(1) Consultant/speaker (2) Speakers Bureau
DiMeglio, Linda	(1) Dampé, Eli Lilly, Mannkind, Provention, Sanofi, Zealand (2) Abata Therapeutics, Tandem, Biomea Fusion	(1) Research Funding (2) Consultant
E. Michael Lewiecki	(1) Amgen, Radius, Kyowa Kirin, Angitia, Ultragenyx, Ascendis, UpToDate, Gilead (2) Amgen, Radius, Ultragenyx, Angitia (3) Amgen, Radius, Kyowa Kirin, Ascendis (4) Amgen, Radius, Angitia, Ascendis, Kyowa Kirin	(1) Stock (2) Research Funding (3) Speakers Bureau (4) Consultant

Fleseriu, Maria	(1) Crinetics, DebioPharm (2) Alexxion, Debiopharm, Crinetics, Camurus, Recordati	(1) Research Funding (2) Consultant
Frieze, Todd	(1) Ascendis Pharma, Interpace Diagnostics (2) Interpace Diagnostics	(1) Speakers Bureau (2) Consultant
Galindo, Rodolfo	(1) Boehringer, Roche, Novo Nordisk, Twiist (2) Amgen, Bayer, Boehringer, Dexcom, Gan&Lee, Eli Lilly, Novo Nordisk, Medtronic	(1) Research Funding (2) Consultant
Garvey, William Timothy	(1) Fractyl Health, Alnylam Pharmaceuticals, Boehringer-Ingelheim, Novo Nordisk, Zealand, Merck, Eli Lilly, Allurion, Inogen, Neurocrine, Carmot/Roche, TERNs Pharmaceuticals, Keros Therapeutics, Regeneron (2) Eli Lilly, Novo Nordisk, Fractyl Health, Alnylam Pharmaceuticals, Inogen, Zealand, Merck, Allurion, Regeneron, Carmot/Roche, Boehringer-Ingelheim,	(1) Stock (2) Consultant
Gigliotti, Benjamin	(1) Horizon Pharmaceutical, Amgen Pharmaceutical, Xeris Pharmaceutical, Immunovant Pharmaceutical, Guidepoint Consulting Network	(1) Consultant
Giraldi, Erica	(1) Recordati, Amryt (2) Camurus, Xeris and Crinetics	(1) Research Funding (2) Advisory Board
Gopalakrishnan, Geetha	(1) Medtronic, Sparrow & Spruce	(1) Research Funding
Gupta, Malini	(1) IBSA, Amgen, Horizon, Ascendis, Chiesi (2) Crinetics, Viridian, Interpace	(1) Speakers Bureau (2) Consultant
Harris, Samantha	(1) Lilly (2) Lilly	(1) Consultant (2) Speakers Bureau

Harris, Yael Tobi	(1)) Marea Therapeutics, Ionis Pharmaceuticals, Novo Nordisk	(1) Research Funding
Hoang, Thanh	(1) Amgen, Acella (2) Horizon, Acella	(1) Speakers Bureau (2) Consultant
Holly F. Lofton	(1) Eli Lilly, Petauri, Structure Therapeutics (2) Novo Nordisk, Eli Lilly, Currax, Inc. (3) Madrigal, Eli Lilly, Novo Nordisk, Medifast	(1) Research Funding (2) Speakers Bureau (3) Consultant
Hurtado Andrade, Maria Daniela	(1) Novo Nordisk, Endogenex, Phenomix Sciences (2) Endogenex, Phenomix Sciences (3) Novo Nordisk	(1) Stock (2) Research Funding (3) Consultant
Iloachimescu, Adriana	(1) Recordati (2) Camurus, Crinetics Pharmaceuticals, Xeris Pharmaceuticals	(1) Research Funding (2) Consultant
Isaacs, Diana	(1) Abbott, Dexcom, Medtronic, Insulet, Lilly, Novo Nordisk, CeQur, Sanofi (2) Lilly, Sanofi, Medtronic, Lifescan, Sequel	(1) Speakers Bureau; (2) Consultant
Izuora, Kenneth	(1) Novo Nordisk	(1) Research Funding
Jaisinghani, Priya	(1) Novo Nordisk, Eli Lilly, corcept, Madrigal (2) Eli Lilly, Madrigal, Novo Nordisk	(1) Speaker's Bureau (2) Consultant
Joshi, Shashank	1) Abbott, Novo Nordisk, Sanofi, Eli Lilly, Bayer, Lupin, Zydus, Alkem, Alembic, USV, DRL, UNS, Cipla, Meyer Organics (2) USV, Marico, Glenmark, Franco Indian, Twin Health, Zydus Lifesciences	1) Speakers Bureau (2) Consultant
Khan, Aliya	(1) Alexion, Ascendis, Amolyt, Bridgebio, Septerna (2) Amgen (3) Amgen	(1) Research Funding (2) Advisory Board (3) Speakers Bureau
Komé, Anne	(1) Dexcom (2) Camurus Pharmaceuticals, Lexicomp/Wolters-Kluwer	(1) Speakers Bureau (2) Consultant

Kotwal, Anupam	(1) Immunovant (2) Ascendis, Veracyte (3) Interpace Diagnostics, Immunovant, Veracyte	(1) Research Funding (2) Speakers Bureau (3) Consultant
Levine, Matthew	1) Novo Nordisk, Ascendis (2) Novo Nordisk	1) Speakers Bureau (2) Consultant
Lieb, David	(1) Immunovant	(1) Research Funding
Look, Michelle	(1) Novo Nordisk, Eli Lilly, Boehringer, Ingelheim, Aadvark Pharmaceuticals (2) Eli Lilly	(1) Consultant (2) Speakers Bureau
Low Wang, Cecilia	(1) Dexcom, Virta Health (2) Dexcom, Virta Health	(1) Research Funding (2) Stock
Malloy, Kevin	(1) Sanofi	(1) Advisory Board
Mechanick, Jeffrey	(1) Abbott, Merck (2) Twin Health, Abbott	(1) Speakers Bureau (2) Consultant
Mehta, Roopa	(1) Abbott, Amgen, Asofarma, Astrazeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Novartis, Sanofi, Silanes (2) Eli Lilly, Abbott	(1) Speakers Bureau (2) Consultant
Melmed, Shlomo	(1) Recordati (2) Recordati, Crinetics, Camurus, Novo Nordisk	(1) Research Funding (2) Consultant
Polsky, Sarit	(1) Dexcom, Inc., Breakthrough T1D, Leona & Harry Helmsley Charitable Trust, NIDDK (2) DexCom, Inc., Eli Lilly, Breakthrough T1D (formerly JDRF), Leona & Harry Helmsley Charitable Trust, NIDDK (3) Medtronic Minimed, Inc.	(1) Stock (2) Research Funding (3) Consultant
Rajpal, Aman	(1) Novo Nordisk, Ionis, Madrigal (2) Madrigal (3) Eli Lilly, Madrigal, Novo Nordisk	(1) Consultant (2) Speakers Bureau (3) Stock

Rinella, Mary	(1) Altimune, Akero, Boehringer Ingelheim, Boston Pharma, GSK, Madrigal, Novo Nordisk, Cytodyn, Lilly, Echosens, 89Bio, Roche, Regeneron (2) Akero, 89Bio, Boehringer Ingelheim, Intercept Pharmaceuticals, Histindex, Madrigal, NGM Biopharmaceuticals, Novo Nordisk, Eli Lilly, Sagimet Biosciences, Sonic Incytes, Cytodyn, GSK and Regeneron	(1) Stock (2) Consultant
Ryan, Donna	Astra Zenica, Biohaven, Boehringer Ingelheim, Calibrate, Carmot/Roche/Genentech, Currax, CinRX, eMed, Epitomee, Fractyl (inactive), i2O, Kailera, Lilly, Nestle, Novo Nordisk, Pfizer, PPD (inactive), Protagonist, Regeneron, Scientific Intake (inactive), Souffle, Source Bio, Structure Therapeutics, Tenvie, Viking, Wondr Health, WW, Zealand (2) Novo Nordisk, Lilly (3) Abbvie, Altimune, Amgen, AstraZeneca, Boehringer Ingelheim, Biohaven, Calibrate, Carmot/Roche/Genentech, CINRx, Currax, eMed, Epitomee, Fractyl, i2O, Lilly, Nestle, Novo Nordisk, Pfizer, Regeneron, Scientific Intake, Source Bio, Structure Therapeutics, Tenvie, Viking, Wondr Health, Zealand	(1) Stock (2) Speakers Bureau (3) Consultant
Samson, Susan	(1) Chiasma, Amryt, Chies, Medthink	(1) Consultant
Schulman-Rosenbaum, Rifka	(1) Sanofi	(1) Consultant

Shah, Viral	(1) Lilly, Enable Bioscience, Zucara Therapeutics, Medtronic, Alexion, Sanofi, NovoNordisk, Dexcom, Insulet, Tandem, Sequel Med Tech, Biomea Fusion, T1D Scout (2) Lilly, Enable Bioscience, Zucara Therapeutics, Medtronic, Dexcom, and Alexion (3) Sanofi, NovoNordisk, Dexcom, Tandem, Medtronic, Biomea Fusion	(1) Stock (2) Research Funding (3) Consultant
Sinha, Avani	(1) Camarus	(1) Consultant
Siraj, Elias	(1) Novo Nordisk; Boehringer Ingelheim, Eli Lilly (2) Boehringer Ingelheim/ Eli Lilly Alliance, Novo Nordisk (3) Novo Nordisk, BI, Eli Lilly	(1) Research funding (2) Speakers Bureau (3) Consultant
Sood, Rachael	(1) Medtronic, Novo Nordisk, Eli Lilly, Dexcom, Sanofi Pharmaceuticals (2) Medtronic, Novo Nordisk, Eli Lilly, Dexcom, Sanofi Pharmaceuticals, Insulet, Sequel Med Tech	(1) Speakers Bureau (2) Consultant
Tabatabai, Laila	(1) Kyowa Kirin (2) Amgen	(1) Research Funding (2) Consultant
Tessnow, Alex	(1) Abbvie, Veridian, Veracyte	(1) Consultant
Toro Tobon, David	(1) Immunovant	(1) Consultant
Vellanki, Priyathama	(1) Astellas Pharmaceuticals (2) Eli Lilly	(1) Stock (2) Consultant
Vidmar, Alaina	(1) Eli Lilly (2) Rhythm Pharmaceuticals, Soleno Pharmaceuticals	(1) Research Funding (2) Consultant
Wermers, Robert	(1) Inozyme Pharma, Acendis, BridgeBio (2) Inozyme	(1) Research Funding (2) Consultant

Wysham, Carol	(1) Abbvie, Eli Lilly, Bayer, Novo Nordisk (2) Eli Lilly, MannKind, Novo Nordisk (3) Abbott, Eli Lilly, MannKind, Novo Nordisk	(1) Research Funding (2) Speakers Bureau (3) Consultant
Zilbermint, Mihail	(1) ROM Tech (2) DexCom, Glucotrack, Inc	(1) Stock (2) Consultant

All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.